RNS Number : 6642A
Shield Therapeutics PLC
04 February 2022

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

KOL Investor Event on Iron Deficiency
Innovation in Iron Deficiency Treatment with a Focus on Clinical Utility of Accrufer®/Feraccru®

Webinar on Thursday 10 February at 10am EST / 3pm GMT

LONDON, UK - 4 February 2022 - Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®(ferric maltol), announces it will host a Key Opinion Leader ("KOL") event for Investors on *"Iron Deficiency Treatment Innovation"* with a focus on clinical utility of Accrufer®/Feraccru® on Thursday 10 February 2022 at 10am (EST) / 3pm (GMT).

The live webinar will feature presentations from:

- **Dr. Lee P. Shulman MD FACMG FACOG (Professor of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois)**, who will discuss the current treatment landscape and unmet medical need in treating patients with iron deficiency.

- **Dr. Carsten Schmidt, MA, FEBGH (Director of Medical Clinic II - Gastroenterology, Hepatology, Endocrinology, Diabetology and Infectious Diseases - Fulda Hospital, Marburg University Medicine)**, who will discuss Shield Therapeutics' potential treatment solution Accrufer®, a stable non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Additionally, members of the Shield senior management team will also be in attendance.

Registration for this event is available through LifeSci Events. A live video webcast will be available in the "Events" section of the Shield corporate website. An archived version of the event will be available on the website for 60 days.

For speaker biographies please visit the website here: https://www.shieldtherapeutics.com/events/

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	+44 (0) 191 511 8500
Hans-Peter Rudolf, CFO	
Nominated Adviser and Joint Broker	
Peel Hunt LLP	
James Steel/Christopher Golden	+44 (0)20 7418 8900
Joint Broker	
finnCap Ltd	
Geoff Nash/Alice Lane/George Dollemore	+44 (0)20 7220 0500
Financial PR & IR Advisor	
Walbrook PR (UK Advisor)	
Paul McManus/Lianne Applegarth/Alice Woodings	+44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)	
LifeSci Advisors, LLC	
John Mullaly	+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®

Shield's lead product Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US and Feraccru® is already being commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

For more information, please visit www.shieldtherapeutics.com or follow Shield on Twitter @ShieldTx.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABLGDDXUGDGDX